Jessica J. O'KOnek

Jessica J. O'KOnek

Auto-generated profile, based on publicly available information

Jessica J. O'KOnek


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2024 in Nature Materials
Verified
Journal Article
Closed access
PDF file
KHKai Han
Kai Han
FXFang Xie
Fang Xie
OAOlamide Animasahun
Olamide Animasahun
MNMinal Nenwani
Minal Nenwani
SKSho Kitamoto
Sho Kitamoto
JMJames Moon
James Moon

11 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PWPamela T Wong
Pamela T Wong
PLPascale R. Leroueil
Pascale R. Leroueil
DSDouglas M. Smith
Douglas M. Smith
SCSusan Ciotti
Susan Ciotti
ABAnna U. Bielinska
Anna U. Bielinska
JBJames R. Baker
James R. Baker
Vaccine adjuvants have been reported to induce both mucosal and systemic immunity when applied to mucosal surfaces and this dual response appears important for protection against certain pathogens. Despite the potential advantages, however, no mucosal adjuvants are currently approved for human use. Evaluating compounds as mucosal adjuvants is a slow and costly process due to the need for lengthy animal immunogenicity studies. We have constructed a library of 112 intranasal adjuvant candidate formulations consisting of oil-in-water nanoemulsions that contain various cationic and nonionic surfactants. To facilitate adjuvant development we first evaluated this library in a series of high-throughput, in vitro assays for activities associated with innate and adaptive immune activation in vivo. These in vitro assays screened for the ability of the adjuvant to bind to mucin, induce cytotoxicity, facilitate antigen uptake in epithelial and dendritic cells, and activate cellular pathways. We then sought to determine how these parameters related to adjuvant activity in vivo. While the in vitro assays alone were not enough to predict the in vivo adjuvant activity completely, several interesting relationships were found with immune responses in mice. Furthermore, by varying the physicochemical properties of the surfactant components (charge, surfactant polar head size and hydrophobicity) and the surfactant blend ratio of the formulations, the strength and type of the immune response generated (TH1, TH2, TH17) could be modulated. These findings suggest the possibility of using high-throughput screens to aid in the design of custom adjuvants with unique immunological profiles to match specific mucosal vaccine applications.

1 June 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
JOJessica J. O'KOnek
Jessica J. O'KOnek
JLJeffrey J. Landers
Jeffrey J. Landers
KJKatarzyna W. Janczak
Katarzyna W. Janczak
RGRishi R. Goel
Rishi R. Goel
AMAnna M. Mondrusov
Anna M. Mondrusov
JBJames R. Baker
James R. Baker

24 February 2022 in Immunotherapy
Verified
Journal Article
Closed access
JLJeffrey J Landers
Jeffrey J Landers
KJKatarzyna W Janczak
Katarzyna W Janczak
ASAkhilesh Kumar Shakya
Akhilesh Kumar Shakya
VZVladimir Zarnitsyn
Vladimir Zarnitsyn
SPSamirkumar R Patel
Samirkumar R Patel
JOJessica J O’konek
Jessica J O’konek
Aim: Epicutaneous immunotherapy (EPIT) with peanut has been demonstrated to be safe but efficacy may be limited by allergen uptake through the skin barrier. To enhance allergen uptake into the skin... Plain language summary Epicutaneous immunotherapy (EPIT) with peanut has been demonstrated to be safe but efficacy has been varied. The tight barrier provided by the skin may limit the amount of al...

7 February 2022 in Frontiers in Allergy
Verified
Journal Article
Open access
KHKevin R. Hughes
Kevin R. Hughes
MSMichael N. Saunders
Michael N. Saunders
JLJeffrey J. Landers
Jeffrey J. Landers
KJKatarzyna W. Janczak
Katarzyna W. Janczak
HTHamza Turkistani
Hamza Turkistani
JOJessica J. O'Konek
Jessica J. O'Konek
Food allergy is a growing health concern worldwide. Current allergen-specific immunotherapy (AIT) approaches require frequent dosing over extended periods of time and may induce anaphylaxis due to allergen-effector cell interactions. A critical need remains to develop novel approaches that refine AIT for the treatment of food allergies. Previous studies show that poly(lactide-co-glycolide) (PLG) nanoscale particles (NP) effectively suppress Th1- and Th17-driven immune pathologies. However, their ability to suppress the distinct Th2-polarized immune responses driving food allergy are unknown. Herein, we describe the safety and efficacy of NPs containing encapsulated peanut allergen in desensitizing murine models of peanut allergy. Peanut extract encapsulation allowed for the safe intravenous delivery of allergen relative to non-encapsulated approaches. Application of 2–3 doses, without the need for dose escalation, was sufficient to achieve prophylactic and therapeutic efficacy, which correlated with suppression of Th2-mediated disease and reduced mast cell degranulation. Efficacy was associated with strong reductions in a broad panel of Th1, Th2, and Th17 cytokines. These results demonstrate the ability of PLG NPs to suppress allergen-specific immune responses to induce a more tolerogenic phenotype, conferring protection from intragastric allergen challenge. These promising studies represent a step forward in the development of improved immunotherapies for food allergy.

1 July 2016 in Vaccine
Verified
Journal Article
Open access
ABAnna U. Bielinska
Anna U. Bielinska
JOJessica J. O’kOnek
Jessica J. O’kOnek
KJKatarzyna W. Janczak
Katarzyna W. Janczak
JBJames R. Baker
James R. Baker
TH2-biased immune responses are associated with inadequate protection against some pathogens and with cancer, colitis, asthma and allergy. Since most currently used vaccine adjuvants induce a TH2-biased response, this has led to interest in developing adjuvants capable of activating TH1 immunity and modulating existing TH2 responses. Immunotherapies to shift immune responses from TH2 to TH1 have generally required prolonged immunization protocols and have not induced effective TH1 responses. We have demonstrated that nanoscale emulsions (NE), a novel mucosal adjuvant, induce robust IgA and IgG antibody responses and TH1/TH17 cellular immunity resulting in protection against a variety of respiratory and mucosal infections. Because intranasal (i.n.) delivery of NE adjuvant consistently induces TH1/TH17 biased responses, we hypothesized that NE could be used as a therapeutic vaccine to redirect existing TH2 polarized immunity towards a more balanced TH1/TH2 profile. To test this, a TH2 immune response was established by intramuscular immunization of mice with alum-adjuvanted hepatitis B surface antigen (HBs), followed by a single subsequent i.n. immunization with NE-HBs. These animals exhibited increased TH1 associated immune responses and IL-17, and decreased TH2 cytokines (IL-4 and IL-5) and IgG1. NE immunization induced regulatory T cells and IL-10, and IL-10 was required for the suppression of TH2 immunity. These data demonstrate that NE-based vaccines can modulate existing TH2 immune responses to promote TH1/TH17 immunity and suggest the potential therapeutic use of NE vaccines for diseases associated with TH2 immunity.